Healthcare -
Biotechnology - NASDAQ - US
$ 1.75
-0.52 %
$ 584 M
Market Cap
-1.43
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart IOVA
FINANCIALS
Balance Sheet
Iovance Biotherapeutics, Inc.
| Current Assets | 457 M |
| Cash & Short-Term Investments | 324 M |
| Receivables | 69.3 M |
| Other Current Assets | 63.9 M |
| Non-Current Assets | 453 M |
| Long-Term Investments | 0 |
| PP&E | 164 M |
| Other Non-Current Assets | 289 M |
| Current Liabilities | 122 M |
| Accounts Payable | 27.5 M |
| Short-Term Debt | 12.9 M |
| Other Current Liabilities | 81.9 M |
| Non-Current Liabilities | 77.7 M |
| Long-Term Debt | 45.4 M |
| Other Non-Current Liabilities | 32.3 M |
EFFICIENCY
Earnings Waterfall
Iovance Biotherapeutics, Inc.
| Revenue | 164 M |
| Cost Of Revenue | 124 M |
| Gross Profit | 40.1 M |
| Operating Expenses | 435 M |
| Operating Income | -395 M |
| Other Expenses | -23.1 M |
| Net Income | -372 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Iovance Biotherapeutics, Inc.
| Net Income | -372 M |
| Depreciation & Amortization | 31.6 M |
| Capital Expenditures | -11.1 M |
| Stock-Based Compensation | 110 M |
| Change in Working Capital | -123 M |
| Others | -5.61 M |
| Free Cash Flow | -364 M |
Wall Street Analysts Price Targets
Iovance Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for IOVA of $12.8 , with forecasts ranging from
a
low of
$2 to a high of $24 .
IOVA Lowest Price Target
Wall Street Target
2 USD
14.29%
IOVA Average Price Target
Wall Street Target
12.8 USD
630.61%
IOVA Highest Price Target
Wall Street Target
24 USD
1271.43%
4. DIVIDEND
ANALYSIS
IOVA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Iovance Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
503 K USD 1
9-12 MONTHS
0 USD 0
Bought
107 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IOVA SHAREHOLDER ALERT: Suffer Losses on Iovance Biotherapeutics? Contact BFA Law by July 14 Securities Fraud Class Action Deadline (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline.
globenewswire.com
- 1 week ago
Is This Beaten-Down Stock a Millionaire Maker?
Over the past two years, Iovance Biotherapeutics (IOVA), a small-cap biotech company, has made significant clinical and regulatory progress. However, the stock has also plunged over this period -- shares are currently trading for less than $2 apiece.
fool.com
- 1 week ago
IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
NEW YORK, July 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
globenewswire.com
- 1 week ago
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 – IOVA
NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
globenewswire.com
- 2 weeks ago
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) and certain of its officers.
globenewswire.com
- 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
globenewswire.com
- 2 weeks ago
The Gross Law Firm Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA
NEW YORK , July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
prnewswire.com
- 2 weeks ago
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
prnewswire.com
- 2 weeks ago
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman
IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline
globenewswire.com
- 2 weeks ago
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
globenewswire.com
- 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
prnewswire.com
- 2 weeks ago
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
LOS ANGELES , July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
prnewswire.com
- 2 weeks ago
8. Profile
Summary
Iovance Biotherapeutics, Inc. IOVA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 584 M
Dividend Yield
0.00%
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Contact
825 Industrial Road, San Carlos, CA, 94070
https://www.iovance.com
IPO
Date
Oct. 15, 2010
Employees
838
Officers
Dr. Igor P. Bilinsky Ph.D.
Chief Operating Officer
Ms. Sara Pellegrino
Senior Vice President of Investor Relations & Corporate Communications
Ms. Tracy Winton
Executive Vice President of Human Resources
Dr. Friedrich Graf Finckenstein M.D.
Chief Medical Officer
Dr. Raj K. Puri M.D., Ph.D.
Chief Regulatory Officer
Mr. Howard B. Johnson M.B.A.
Chief Business Officer
Mr. Kevin Smyth
Executive Vice President of Quality
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director
Mr. Jean-Marc Bellemin M.B.A.
Chief Financial Officer, Principal Accounting Officer & Treasurer
Mr. Brian Shew M.B.A.
Senior Vice President & Head of Digital and Information Technology